Alterity Therapeutics Ltd has released a press release.
Response to ASX Price Query
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Alterity Therapeutics to Provide Corporate Update in Fireside Chat
- Alterity Therapeutics Prominently Featured at the International MSA Congress
- Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
- Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
- Alterity Granted U.S. FDA Fast Track Designation for ATH434
Later from Alterity Therapeutics
- Peer-Reviewed Publication on Novel MRI Endpoint from bioMUSE
- Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study
- Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy
- Positive ATH434 Results from Open-Label Phase 2 Trial in MSA
- Appendix 4C – Q4 FY25 Quarterly Cash Flow Report
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics